GSK vs INTC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 22, 2026

GSK

53.7
AI Score
VS
GSK Wins

INTC

51.9
AI Score

Investment Advisor Scores

GSK

54score
Recommendation
STRONG BUY

INTC

52score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK INTC Winner
Forward P/E 21.2314 72.9927 GSK
PEG Ratio 106.1749 0.5009 INTC
Revenue Growth 5.3% 25.4% INTC
Earnings Growth -69.5% -71.7% GSK
Tradestie Score 53.7/100 51.9/100 GSK
Profit Margin 14.5% -19.8% GSK
Beta 1.00 1.00 Tie
AI Recommendation STRONG BUY HOLD GSK

Relative Price Performance (Last 90 Days)

GSK 1M: +3.3% · 3M: +1.7% INTC 1M: -10.1% · 3M: -24.0%

Current Technical Phase

GSK

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54

RSI (14): 54.2 · Price: $52.41

INTC

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 39

RSI (14): 39.4 · Price: $90.07

Fundamentals Snapshot

Metric GSK INTC
Market Cap
Forward P/E 10.2 44.2
Trailing P/E 16.3
Revenue (TTM)
Revenue Growth 0.1% 0.3%
Gross Margin 0.7% 0.4%
Operating Margin 0.3% 0.1%
EPS 3.19 -2.09
Dividend Yield 0.04%

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.